CompanyDrug

Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma

CompanyDrug

CSPC Pharmaceutical Secures NMPA Clinical Trial Approval for SYS6051, a Tissue Factor-Targeted ADC for Advanced Solid Tumors

CompanyDeals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development
CompanyDeals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

CompanyDrug

Luye Pharma Initiates Phase II Trial of LY03017 for Alzheimer’s-Associated Psychosis in China Following US Clinical Clearance

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235
CompanyDeals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision
CompanyDeals

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision

CompanyDeals

Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers

3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem
CompanyDeals

3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem

CompanyDeals

Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment

Bayer AG Secures NMPA Approval for Hyrnuo (Sevabertinib) to Treat HER2-Mutant NSCLC in China
Others

Bayer AG Secures NMPA Approval for Hyrnuo (Sevabertinib) to Treat HER2-Mutant NSCLC in China

Johnson & Johnson Partners with Shanghai Pharmaceuticals for Exclusive Promotion of Paliperidone Palmitate Long-Acting Injection in China
CompanyDeals

Johnson & Johnson Partners with Shanghai Pharmaceuticals for Exclusive Promotion of Paliperidone Palmitate Long-Acting Injection in China